Climb Bio, Inc. Quarterly Cash, Cash Equivalents, and Short-term Investments in USD from Q4 2021 to Q4 2022
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.
-
Summary
-
Climb Bio, Inc. quarterly Cash, Cash Equivalents, and Short-term Investments history and growth rate from Q4 2021 to Q4 2022.
- Climb Bio, Inc. Cash, Cash Equivalents, and Short-term Investments for the quarter ending December 31, 2022 was $124M, a 23.4% decline year-over-year.
Cash, Cash Equivalents, and Short-term Investments, Quarterly (USD)
Cash, Cash Equivalents, and Short-term Investments, YoY Quarterly Growth (%)